USD 0.0
(9900.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2022 | - USD | 0.0% |
2021 | - USD | 100.0% |
2020 | -1816.00 USD | 96.88% |
2019 | -58.17 Thousand USD | 7.95% |
2018 | -63.2 Thousand USD | 4.37% |
2017 | -66.08 Thousand USD | -230.01% |
2016 | -20.02 Thousand USD | -102.51% |
2015 | -9889.00 USD | 0.0% |
2014 | - USD | -100.0% |
2013 | 40.04 Thousand USD | -88.5% |
2012 | 348.25 Thousand USD | 0.0% |
2011 | - USD | -100.0% |
2010 | 244.47 Thousand USD | -45.05% |
2009 | 444.94 Thousand USD | -54.86% |
2008 | 985.81 Thousand USD | 313.89% |
2007 | 238.18 Thousand USD | 220.26% |
2006 | -198.05 Thousand USD | 0.0% |
2005 | - USD | 0.0% |
2004 | - USD | 0.0% |
2003 | - USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
1999 | - USD | -100.0% |
1998 | 4.55 Million USD | 34.26% |
1997 | 3.39 Million USD | 438.03% |
1996 | 630.48 Thousand USD | 64.98% |
1995 | 382.15 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2022 FY | - USD | 0.0% |
2021 FY | - USD | 100.0% |
2020 Q1 | - USD | 0.0% |
2020 FY | -1816.00 USD | 96.88% |
2020 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2019 FY | -58.17 Thousand USD | 7.95% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2018 FY | -63.2 Thousand USD | 4.37% |
2017 Q1 | - USD | 0.0% |
2017 FY | -66.08 Thousand USD | -230.01% |
2016 Q3 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | -20.02 Thousand USD | -102.51% |
2016 Q4 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 FY | -9889.00 USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2014 Q1 | - USD | 100.0% |
2014 Q2 | - USD | 0.0% |
2014 FY | - USD | -100.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2013 Q3 | 183.04 Thousand USD | -25.42% |
2013 FY | 40.04 Thousand USD | -88.5% |
2013 Q1 | 248.96 Thousand USD | -23.21% |
2013 Q2 | 245.42 Thousand USD | -1.42% |
2013 Q4 | -637.39 Thousand USD | -448.22% |
2012 Q4 | 324.2 Thousand USD | 16534.33% |
2012 FY | 348.25 Thousand USD | 0.0% |
2012 Q3 | 1949.00 USD | -72.46% |
2012 Q2 | 7078.00 USD | -52.89% |
2012 Q1 | 15.02 Thousand USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q1 | - USD | -100.0% |
2011 Q4 | - USD | 0.0% |
2011 FY | - USD | -100.0% |
2011 Q3 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 FY | 244.47 Thousand USD | -45.05% |
2010 Q1 | - USD | 100.0% |
2010 Q2 | - USD | 0.0% |
2010 Q4 | 244.47 Thousand USD | 0.0% |
2009 Q2 | 6996.00 USD | -95.68% |
2009 Q3 | 235.91 Thousand USD | 3272.17% |
2009 Q4 | -189.9 Thousand USD | -180.5% |
2009 Q1 | 161.81 Thousand USD | -50.47% |
2009 FY | 444.94 Thousand USD | -54.86% |
2008 FY | 985.81 Thousand USD | 313.89% |
2008 Q2 | 312.58 Thousand USD | 13.54% |
2008 Q3 | 71.17 Thousand USD | -77.23% |
2008 Q4 | 326.74 Thousand USD | 359.05% |
2008 Q1 | 275.3 Thousand USD | 73.45% |
2007 Q4 | 158.72 Thousand USD | 249.65% |
2007 Q3 | 45.39 Thousand USD | 258.15% |
2007 Q2 | -28.7 Thousand USD | -145.73% |
2007 FY | 238.18 Thousand USD | 220.26% |
2007 Q1 | 62.76 Thousand USD | 146.16% |
2006 FY | -198.05 Thousand USD | 0.0% |
2006 Q4 | -135.96 Thousand USD | -368.01% |
2006 Q3 | -29.05 Thousand USD | -52.49% |
2006 Q2 | -19.05 Thousand USD | -36.22% |
2006 Q1 | -13.98 Thousand USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 FY | - USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2004 Q3 | - USD | 0.0% |
2004 Q4 | - USD | 0.0% |
2004 Q2 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
2004 Q1 | - USD | 0.0% |
2003 FY | - USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2003 Q2 | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
2000 Q2 | - USD | 0.0% |
2000 Q1 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
1999 FY | - USD | -100.0% |
1999 Q4 | - USD | 0.0% |
1998 Q3 | 1.15 Million USD | 284.73% |
1998 FY | 4.55 Million USD | 34.26% |
1998 Q1 | 400 Thousand USD | -33.33% |
1998 Q2 | 300 Thousand USD | -25.0% |
1997 FY | 3.39 Million USD | 438.03% |
1997 Q4 | 600 Thousand USD | -32.75% |
1997 Q3 | 892.16 Thousand USD | 546.08% |
1997 Q2 | -200 Thousand USD | -300.0% |
1997 Q1 | 100 Thousand USD | 116.67% |
1996 FY | 630.48 Thousand USD | 64.98% |
1996 Q1 | 200 Thousand USD | 0.0% |
1996 Q2 | 200 Thousand USD | 0.0% |
1996 Q3 | 230.48 Thousand USD | 15.24% |
1996 Q4 | -600 Thousand USD | -360.33% |
1995 Q4 | 200 Thousand USD | 0.0% |
1995 FY | 382.15 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
America Great Health | 168.58 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 100.0% |
Aridis Pharmaceuticals, Inc. | - USD | NaN% |
Biora Therapeutics, Inc. | -551 Thousand USD | 100.0% |
Bio-Path Holdings, Inc. | -178 Thousand USD | 100.0% |
Better Therapeutics, Inc. | -2.72 Million USD | 100.0% |
Calithera Biosciences, Inc. | -1.38 Million USD | 100.0% |
Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 100.0% |
eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.0% |
Eloxx Pharmaceuticals, Inc. | - USD | NaN% |
Evelo Biosciences, Inc. | - USD | NaN% |
Evolutionary Genomics, Inc. | -1.02 Million USD | 100.0% |
Finch Therapeutics Group, Inc. | -7.09 Million USD | 100.0% |
Galera Therapeutics, Inc. | -259 Thousand USD | 100.0% |
Innovation1 Biotech Inc. | -52.69 Thousand USD | 100.0% |
Kiromic BioPharma, Inc. | -2.79 Million USD | 100.0% |
Molecular Templates, Inc. | 50.39 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 100.0% |
NexImmune, Inc. | -1.02 Million USD | 100.0% |
Orgenesis Inc. | -5.72 Million USD | 100.0% |
Panbela Therapeutics, Inc. | -25.64 Million USD | 100.0% |
Point of Care Nano-Technology, Inc. | -4601.00 USD | 100.0% |
PaxMedica, Inc. Common Stock | - USD | NaN% |
Scopus BioPharma Inc. | - USD | NaN% |
Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.0% |
Statera Biopharma, Inc. | -488.31 Thousand USD | 100.0% |
TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 100.0% |
Trevena, Inc. | 1.45 Million USD | 100.0% |
Vaxxinity, Inc. | -2.23 Million USD | 100.0% |
Vaccinex, Inc. | -16 Million USD | 100.0% |
Vicapsys Life Sciences, Inc. | - USD | NaN% |
Viracta Therapeutics, Inc. | -492 Thousand USD | 100.0% |
ZIVO Bioscience, Inc. | 11.61 Thousand USD | 100.0% |